Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- COVID-19-Disrupted Air Freight Hitting Commodity Transports, but No Major Impact So Far on Drugs
March 26, 2020
- Fujifilm Launches Contract Services for Process Development, Manufacturing of Liposome Formulations
March 26, 2020
- Asahi Kasei’s US Subsidiary Turbocharges Ventilator Production amid Coronavirus Outbreak
March 26, 2020
- Face Mask Shortages Crippling Drug Makers’ Business Activities, Travel Restrictions Could Delay Approval
March 26, 2020
- Aspen Japan President to Lead Sandoz K.K.
March 26, 2020
- Boehringer Ingelheim Recalling Alesion after Impurities Detected
March 25, 2020
- Astellas Inks Biotech R&D Pact for Next-Gen I/O Therapy
March 25, 2020
- AnGes Now Ready to Launch Preclinical Study for Coronavirus DNA Vaccine
March 25, 2020
- Nippon Chemiphar Snaps Up Japan Rights for Tumor Microenvironment Therapy from Delta-Fly
March 25, 2020
- Novartis Japan to Shed Oncology Staffers amid Overall Downscaling
March 24, 2020
- Chugai Mulling Japan Actemra Trial for COVID-19; Sanofi Says No Kevzara Plan for Now
March 24, 2020
- Chugai, Roche, Genentech File Patent Suit against Fresenius Kabi over Alecensa
March 24, 2020
- KM Biologics, Takeda to Wind Up Sales Partnership on Flu Vaccine
March 24, 2020
- Mochida, Gene Techno Science Pair Up for Regenerative Medicines for Rare Gastrointestinal Diseases
March 24, 2020
- Takeda’s Entyvio Approved in China
March 24, 2020
- Kitasato Institute Embarks on Drug Screening Project for COVID-19
March 23, 2020
- Oncolys to Create US Non-Clinical Research Subsidiary, Accelerating Drug R&D
March 23, 2020
- Eiken’s Novel Coronavirus Detection Reagent Kit Bags Public Insurance Coverage
March 23, 2020
- Asahi Kasei Grabs Global Rights for SBI Biotech’s Autoimmune Disease Therapy
March 23, 2020
- Fujifilm to Scale Up Production Capacity at UK Subsidiary with 9 Billion Yen Investment
March 23, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…